Platelet activation and inhibition in polycythemia vera and essential thrombocythemia

Blood

Volumn 121, Issue 10, 2013, Pages 1701-1711

  Patrono, Carlo ^a   Rocca, Bianca ^a   De Stefano, Valerio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DIPYRIDAMOLE; HYDROXYUREA; NONSTEROID ANTIINFLAMMATORY AGENT; THROMBOXANE A2; THROMBOXANE B2;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; KIDNEY CELL; LOW DRUG DOSE; LUNG EMBOLISM; POLYCYTHEMIA VERA; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

EID: 84876459970     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-429134     Document Type: Article

References (97)

1. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115(17):3842-3847.
2. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123(9): 656-664.
3. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10): 755-761. (Pubitemid 39482529)
4. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10): 2224-2232. (Pubitemid 46218714)
5. Vannucchi AM. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med. 2010;5(3):177-184.
6. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(3):284-293.
7. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995;74(5): 1225-1230.
8. Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirinsuppressible platelet activation in vivo. Blood. 1992;80(8):1965-1971.
9. Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood. 2002;99(7):2612-2614. (Pubitemid 34525455)
10. Arellano-Rodrigo E, Alvarez-Larr'an A, Reverter JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84(2): 102-108.
11. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24): 2482-2494.
12. Vejar M, Fragasso G, Hackett D, et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemost. 1990;63(2):163-168. (Pubitemid 20128175)
13. Ciabattoni G, Ujang S, Sritara P, et al. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. J Am Coll Cardiol. 1993;21(6):1377-1381. (Pubitemid 23138705)
14. van Kooten F, Ciabattoni G, Koudstaal PJ, et al. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke. 1999;30(3):546-549. (Pubitemid 29115390)
15. Santilli F, Davì G, Consoli A, et al. Thromboxanedependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47(2):391-397. (Pubitemid 43063260)
16. Davì G, Guagnano MT, Ciabattoni G, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002; 288(16):2008-2014. (Pubitemid 35204691)
17. Davì G, Alessandrini P, Mezzetti A, et al. In vivo formation of 8-Epi-prostaglandin F2 a is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1997;17(11):3230-3235. (Pubitemid 28016082)
18. Di Minno G, Davì G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92(3):1400-1406. (Pubitemid 23273917)
19. Ciabattoni G, Davì G, Collura M, et al. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am J Respir Crit Care Med. 2000; 162(4 pt 1):1195-1201.
20. Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost. 2007;5(3):490-496. (Pubitemid 46680680)
21. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009;101(1): 151-156.
22. Watanabe K, Takeuchi K, Kawai Y, et al. Automated measurement of reticulated platelets in estimating thrombopoiesis. Eur J Haematol. 1995;54(3):163-171.
23. Moles-Moreau MP, Ternisien C, Tanguy-Schmidt A, et al. Flow cytometry-evaluated platelet CD36 expression, reticulated platelets and platelet microparticles in essential thrombocythaemia and secondary thrombocytosis. Thromb Res. 2010; 126(5):e394-e396.
24. Panova-Noeva M, Marchetti M, Buoro S, et al. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011;118(9):2599-2601.
25. Pascale S, Petrucci G, Dragani A, et al. Aspirininsensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15): 3595-3603.
26. Michiels JJ, Berneman Z, Schroyens W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadinresistant arterial thrombophilia. Platelets. 2006; 17(8):528-544. (Pubitemid 44837723)
27. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and pointof-care diagnostic algorithms. Leukemia. 2008; 22(1):14-22.
28. Tefferi A, Skoda R, Vardiman JW. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 2009;6(11):627-637.
29. De Stefano V, Za T, Rossi E, et al GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3): 372-380. (Pubitemid 351398638)
30. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8(3): 556-562. (Pubitemid 20087557)
31. Colombi M, Radaelli F, Zocchi L, et al. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer. 1991;67(11):2926-2930.
32. Harrison CN, Campbell PJ, Buck G, et al; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1): 33-45. (Pubitemid 41007805)
33. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11): 1645-1651.
34. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112(8):3135-3137.
35. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22):5857-5859.
36. Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(4):716-719.
37. Palandri F, Polverelli N, Catani L, et al. Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients. Br J Haematol. 2012; 156(2):281-284.
38. McIntyre KJ, Hoagland HC, Silverstein MN, et al. Essential thrombocythemia in young adults. Mayo Clin Proc. 1991;66(2):149-154.
39. Ruggeri M, Finazzi G, Tosetto A, et al. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998; 103(3):772-777. (Pubitemid 28545314)
40. Alvarez-Larr'an A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8): 1205-1210, quiz 1387.
41. Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood. 2012;120(3):569-571.
42. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 2012;25(3):235-242.
43. Landolfi R, Marchioli R, Kutti J, et al European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124.
44. Baigent C, Blackwell L, Collins R, et al Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860.
45. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ. 2006; 332(7553):1302-1308.
46. Becattini C, Agnelli G, Schenone A, et al WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366(21):1959-1967.
47. Patrono C, Garc'ia Rodr'iguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22): 2373-2383. (Pubitemid 41713749)
48. Barbui T, Barosi G, Birgegard G, et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
49. Michiels JJ, Abels J, Steketee J, et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985;102(4): 466-471. (Pubitemid 15109002)
50. van Genderen PJ, Mulder PG, Waleboer M, et al. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol. 1997;97(1):179-184. (Pubitemid 27179585)
51. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132-1136.
52. Tartaglia AP, Goldberg JD, Berk PD, et al. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 1986;23(3):172-176.
53. Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(7):1409-1411.
54. Castaman G, Lattuada A, Ruggeri M, et al. Platelet von Willebrand factor abnormalities in myeloproliferative syndromes. Am J Hematol. 1995;49(4):289-293.
55. Budde U, Dent JA, Berkowitz SD, et al. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood. 1986;68(6):1213-1217. (Pubitemid 17228794)
56. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood. 2006;108(7):2493-2494. (Pubitemid 44497538)
57. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002;99(11):7634-7639. (Pubitemid 34568743)
58. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978;61(2):314-319. (Pubitemid 8280401)
59. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72(6):1177-1184. (Pubitemid 16126796)
60. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance." J Am Coll Cardiol. 2009;53(8):667-677.
61. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17(3-4):317-327. (Pubitemid 10129020)
62. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69(6):1366-1372. (Pubitemid 12081064)
63. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
64. Frelinger AL, III, Li Y, Linden MD, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009;120(25):2586-2596.
65. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69(1):180-186. (Pubitemid 17007095)
66. Smith JP, Haddad EV, Taylor MB, et al. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. Hypertension. 2012;59(3):719-725.
67. Blais N, Pharand C, Lordkipanidz'e M, et al. Response to aspirin in healthy individuals. Crosscomparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost. 2009;102(2):404-411.
68. Lordkipanidz'e M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28(14):1702-1708. (Pubitemid 47227104)
69. Muir AR, McMullin MF, Patterson C, et al. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart. 2009;95(15):1225-1229.
70. Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation. 2012; 125(10):1288-1303, discussion 1303.
71. Michelson AD, Cattaneo M, Eikelboom JW, et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005;3(6):1309-1311.
72. Tefferi A. Overcoming "aspirin resistance" in MPN. Blood. 2012;119(15):3377-3378.
73. Gruppo Italiano Studio Policitemia Vera (GISP) Low-dose aspirin in polycythaemia vera: a pilot study. Br J Haematol. 1997;97(2):453-456.
74. Dragani A, Pascale S, Recchiuti A, et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirintreated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2010;115(5): 1054-1061.
75. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSETthrombosis). Blood. 2012;120(26):5128-5133.
76. The European Agency for the Evaluation of Medicinal Products. Position paper on the regulatory requirements for the authorisation of low-dose modified release ASA formulations in the secondary prevention of cardiovascular events. EMEA/CPMP/EWP/282/02/Final. http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003340.pdf. Accessed January 30, 2013.
77. Flossmann E, Rothwell PM. British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603-1613. (Pubitemid 46710123)
78. Rothwell PM, Wilson M, Elwin CE, et al. Longterm effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754): 1741-1750.
79. Rothwell PM, Fowkes FGR, Belch JFF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.
80. Rothwell PM, Price JF, Fowkes FGR, et al. Shortterm effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826): 1602-1612.
81. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321(3):129-135.
82. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-1304.
83. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252-266. (Pubitemid 34196319)
84. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9(5):259-267.
85. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000;60(17):4705-4708.
86. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348(10):883-890. (Pubitemid 36297996)
87. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891-899. (Pubitemid 36297997)
88. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125(2): 328-336. (Pubitemid 36929412)
89. Logan RFA, Grainge MJ, Shepherd VC, et al; ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134(1):29-38. (Pubitemid 350309319)
90. Baron JA, Sandler RS, Bresalier RS, et al APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131(6): 1674-1682. (Pubitemid 44958508)
91. Bertagnolli MM, Eagle CJ, Zauber AG, et al APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873-884. (Pubitemid 44315980)
92. Patrono C, Patrignani P, Garc'ia Rodr'iguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108(1):7-13. (Pubitemid 32634915)
93. Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118(25):6515-6520.
94. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1-2):1-13. (Pubitemid 26402780)
95. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71(3):676-688. (Pubitemid 13160815)
96. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27(18): 2991-2999.
97. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32(23):2922- 2932.